Pharmasaga Company Limited
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Currently, Pharmasaga has two Pdia4 inhibitors, PS-001 and PS-002, for type 2 diabetes (T2D) and type 1 diabetes (T1D), respectively. Their pre-clinical studies were completed in 2021.
US FDA approved the application of investigation drug (IND), PS-001. W
US FDA approved the application of investigation drug (IND), PS-001. W
The content above was translated by Ai
Founded Year
2021
Unified Business No.
83379922
Status
Active
Number of Employees
14
Total Paid-in
Capital
561,365,800 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Pharmasaga is a spin-off of Academia Sinica and was founded in Jan 2021. Our core technology is a drug discovery platform composed of molecular docking, chemistry and biology for drug discovery, developed by Dr Wen-Chin Yang, Academia Sinica. With this platform, we developed first-in-class Pdia4 inhibitors for diabetes. The Pdia4 inhibitors can be used as a brand-new beta cell-centric approach to reducing beta cell failure and, in turn, diabetes. More importantly, the Pdia4 inhibitors can reverse diabetes alone and in combination with metformin.
The content above was translated by Ai
